Klaus Metzeler: Some of my (secret) favourites in the AML/MDS field
Klaus Metzeler, at University of Leipzig, shared on X/Twitter:
“As the ASH 23 at The American Society of Haematology (ASH) scientific program is about to kick off in sunny San Diego, here are some of my (secret) favourites in the AML/MDS field 1/n – feel free to add your favourites.
Abstract 61 by Gregor Hörmann/ MLL: This abstract shows that while ICC classification introduced the new MDS/AML category, outcomes of these patients is distinct from ‘classical’ AML and the ELN risk stratification doesn’t apply here.
Abstract 967 by M. Hunault-Berger et al.: the french Backbone Intergroup intergroup BIG-1 study should finally settle the question of AraC 1.5g/m2 versus 3g/m2 in consolidation across ELN-22 subgroups… or maybe not, as most patients didn’t receive TKIs or GO?
Abstract 425 by J Othman et al f/ MRC group: MRD-guided post remission treatment seems to work in NPM1mut AML. Pts who were MRD+ in PB after cycle 2 benefited from alloSCT in CR1, those with MRDneg (including those who also had FLT3-ITD) had good outcomes without transplant.
Abstract 160 from the German SAL group, presented by L.Runke: Salvage treatment with Venetoclax + HAM in fit pts with R/R AML. Response rates encouraging and 16/31 responders progressed to alloSCT. An alternative to FLAG-Ida-Ven, maybe with lower toxicity?
Abstract 833 by A. Bazinet et al: Fully oral AML therapy with decitabine/cedazuridine (ASTX727) and venetoclax. This was a very high risk phase 2 cohort (median age ~80y, almost 80% ELN-22 adverse risk) and considering this, OS in frontline and tolerability look promising.
Late breaking abstract LBA-5 by I. Aldoss et al: Revumenib monotherapy in KMT2Ar acute leukemia, an interim analysis of a phase 2 trial. CRc rate of >40% and (truly…) ‘manageable’ toxicities. I’m curious to see more data in the larger NPM1mut population and combination regimens!
Late breaking abstract LBA-5 by I. Aldoss et al: Revumenib monotherapy in KMT2Ar acute leukemia, an interim analysis of a phase 2 trial. CRc rate of >40% and (truly…) ‘manageable’ toxicities. I’m curious to see more data in the larger NPM1mut population and combination regimens!
Abstract 197 by Tentori et al.: A ‘virtual clinical trial’ prediciting the best time point for alloSCT in MDS. Lower-risk patients benefit from delayed Tx while HR pts need transplant soon. Importantly, IPSS-M is more informative than IPSS-R . Web calculator to be presented!
Abstract 196 by Diez-Campelo et al.: Ph2 data on KER050, a new Activin/TGFb signaling inhibitor in LR MDS. Responses seen in pts with/without ring sideroblasts, often durable. Also positive effects on platelet count. And we’re proud University of Leipzig to be a central lab for this trial.
Abstract 319 by JS Garcia et al. – more data on venetoclax and azacitidin in HR MDS, from a dose expansion cohort of 107 pts. mORR (including marrow CR) of 80% and 30% true CR, but also significant hematotoxicity – looking forward to see the phase 3 VERONA trial data.”
Source: Klaus Metzeler/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023